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Cancer cells are now revealing their metabolic secrets with a combination of biochemical ap-
proaches and omic-level analyses. This issue’s Select highlights articles that begin to clarify how
cells aremetabolically rewired during oncogenesis, reporting new functions formetabolic enzymes,
delineating unexpected biosynthetic processes, and identifying potential therapeutic targets.Cells normally condense glutamine-derived oxalo-
acetate with glucose-derived acetyl-CoA to pro-
duce citrate (left), whereas cells with defective
mitochondria reverse part of CAC using NADPH-
dependent isocitrate dehydrogenases (IDHs) to
convert a-ketoglutarate (a-kg) to isocitrate via
reductive carboxylation (right). Diagram courtesy
of R. Deberardinis.Reversing around a Metabolic Corner
Mitochondria provide cells with much more than ATP produced via the elec-
tron transport chain (ETC). Cancer cells are no exception. Although many
cancer cells rely primarily on aerobic glycolysis for their energy, they still
rely on mitochondria to produce precursors for fatty acid synthesis and
other biosynthetic processes. How tumor cells with defective mitochondria
produce the lipids necessary for proliferation has been unclear. Mullen
et al. (2011) uncover new metabolic flexibility in cancer cells. Glutamine can
drive citric acid cycle (CAC) reactions in reverse, such that reductive carbox-
ylation yields acetyl-CoA for lipid synthesis. Glutamine-dependent reductive
carboxylation hasbeen recognizedas aminor source of citrate inmammalian
cells and as the major source of citrate and acetyl-CoA in P. falciparum,
a parasite with limited respiration. By tracing the fate of carbons supplied
to osteosarcoma cells by 13C-glucose or 13C-glutamine, the authors identify
reductive carboxylation as the major source of acetyl-CoA in ETC-deficient
cancer cells. Although some tumors carry mutations in ETC components,
oncogenic mutations are more commonly found in CAC enzymes like fuma-
rate hydratase (FH). To testwhether these typesofmutationsalso favor gluta-
mine-dependent reductive carboxylation, Mullen et al. (2011) examinedthe metabolism of renal tumor cells lacking FH activity. When cultured without glutamine, these cells stop proliferating.
In the presence of glutamine, FH-deficient cells proliferate by employing both oxidative glutamine metabolism (a process
well-known for replenishingCAC intermediates that are depleted under normal growth conditions) and reductive carboxylation
of glutamine (contributing lipid building blocks). Despite the association between defective mitochondria and oncogenesis,
this study highlights the central importance of mitochondria in cancer, even when they aren’t generating ATP.
Mullen, A., et al. (2011). Nature 481, 385–358.Crystal structure of the glutaminase tetramer with
BPTES bound at the dimerization interfaces. Image
courtesy of A. Ambrosio and C. Dang.Myc Moves Metabolism
Biosynthetic processes can deplete citric acid cycle (CAC) intermediates and
thus slow down or block CACprogression. Previous work has shown that this
type of anaplerosis depends on Myc-regulated glutamine breakdown. Two
recent studies offer new insights into the importance of Myc-dependent
glutaminolysis. Le et al. (2012) extend the role of Myc-driven glutaminolysis
to B cell lymphoma and hypoxic tumor cell proliferation, where it feeds a
glucose-independent CAC. Under hypoxic conditions, they show that Myc
also regulates the production of glutathione from glutamine, enabling ROS
detoxification and redox homeostasis. To address whether disrupting gluta-
minolysismayhalt tumorgrowth, Leandcolleaguesfirst treatedMyc-express-
ing B cells with the glutaminase inhibitor BPTES. Under normoxia, the cells
proliferate more slowly. Under hypoxia, the cells stop dividing and undergo
apoptosis. In a xenograft model treated with BPTES, Myc-dependent tumors grow more slowly, suggesting that inhibition of
glutaminolysismayprovide therapeutic benefits. Further solidifying the links betweenMyc, glutamine catabolism, and cell prolif-
eration,Wanget al. (2011), highlight the similarities between rapidly dividingcancer cells and activatedTcells. By tracing the fate
of labeled glutamine and glucose in activated T cells, Wang and colleagues delineate a Myc-dependent metabolic route from
glutamine tocommonbiosyntheticprecursors.Theauthorsperformedmetabolomics,metabolic fluxanalysis, and transcriptom-
ics to understand how Myc can shift metabolic pathways from energy production towards biosynthesis. Because Myc is
expressed at similar levels in activated T cells and transformed cells, it is likely that the metabolic rewiring that occurs during
an acute shift towards rapid cell proliferation may underlie long-term metabolic changes associated with lymphomas.
Le, A., et al. (2012). Cell Met. 15, 110–121.
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Xenograft of tumors from cancer cells
expressing dimeric mutant PKM2 (far
right), which grow more rapidly than
those from cells expressing wild-type
PKM2. Image courtesy of Z. Liu.PEP Rallies PKM2 for STAT
Glycolytic enzymes are highly upregulated and/or misregulated in cancer cells. One
such enzyme is the embryonic M2 isoform of pyruvate kinase (PKM2), which is highly
expressed in nearly all human tumors. Unlike PKM1, the common adult isoform that
efficiently generates pyruvate and ATP from phosphoenolpyruvate (PEP) and ADP,
PKM2 is modulated so that upstream glycolytic intermediates are shunted into
biosynthetic pathways. Gao et al. (2012) now present data that PKM2 can act as
a protein kinase capable of activating progrowth transcription factors. PKM2 exists
in an active tetrameric form and a metabolically inactive dimeric form. Previous
studies suggest that interaction with phosphotyrosine peptides converts the enzyme
from the tetrameric to dimeric form, modulating PKM2 activity. Previous reports have
noted that PKM2 can be found in the nucleus where it appears to act as a transcrip-
tional coactivator. Now, Gao and coworkers show that dimeric, not tetrameric, PKM2
localizes to the nucleus in cancer cells. With a series of in vitro and cell culture exper-
iments, they provide evidence that dimeric PKM2 transfers a phosphate from PEP toa single tyrosine residue of STAT3, bypassing JAK and Src kinase control over this transcription factor. With structure-based
mutant analysis, they support a model in which PKM2’s protein substrates bind to the site normally occupied by ADP.
Gao et al. conclude their study by testing the contribution of dimeric PKM2 to tumor formation. They find that xenografted
adenocarcinoma cells, which carry a mutant form of PKM2 that preferentially forms dimers, grow more rapidly and appear
more aggressive than cells carryingwild-type PKM2. Together these data provide an explanation for the historical observation
that malignant cells exhibit prolonged STAT3 activation and suggest an unexpected repurposing of PKM2 during oncogenic
transformation.
Gao, X., et al. (2012). Mol. Cell. Published online February 2, 2012. 10.1016/j.molcel.2012.01.001.Nonmetabolic functions of PKM2 pro-
mote cell-cycle progression via activa-
tion of b-catenin-regulated gene expres-
sion. Diagram courtesy of Z. Lu.PKM2 Partners for Proliferation
Mutations in the growth factor receptor EGFR promote uncontrolled proliferation and
are linked to multiple types of cancers, including glioblastoma, astrocytoma, and
small cell lung carcinoma. In a recent report, Yang et al. (2011) connect EGFR activa-
tion to metabolic reprogramming, providing new insight into how expression of PKM2
contributes to oncogenesis. The authors reveal that in addition to its metabolic role,
PKM2 acts as a transcriptional cofactor that works with b-catenin to promote expres-
sion of cell-cycle genes. Unlike recent work showing that PKM2 interacts with HIF1a,
Yang and colleagues find that binding between PKM2 and b-catenin occurs during
normoxia and requires phosphorylation of b-catenin on a single tyrosine residue by
c-Src. Previous reports have shown that phosphotyrosine peptides can allosterically
tune PKM2 activity, but whether binding between PKM2 and phosphotyrosine
peptides provides other advantages remains unclear. Now, the results from Yang
et al. (2011) directly link the interaction between PKM2 and tyrosine-phosphorylated
b-catenin to cancer cell proliferation, illustrating that this protein complex drives Wnt-
independent expression of cyclin D1. The authors demonstrate that depletion of
b-catenin or PKM2 in EGFR-activated cells inhibits their ability to form tumors, and the authors provide evidence that the
b-catenin-PKM2 complex is important for tumor formation. Administration of a Src inhibitor reduces levels of tyrosine-phos-
phorylated b-catenin and inhibits brain tumor formation in mice. Importantly, both high levels of tyrosine-phosphorylated
b-catenin and nuclear PKM2 correlate with poor prognosis of glioblastoma and astrocytoma. These data point towards
a way to improve diagnosis and treatment of tumors with activated EGFR. Together with recent reports, including the one
profiled above, this study illustrates that PKM2 plays both metabolic and nonmetabolic roles in tumorigenesis and identifies
PKM2 as a key controller of oncogenic changes.
Yang, W., et al. (2011). Nature 480, 118–123.
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